Expression levels of CYP genes displayed as cycle threshold (Ct) values in 13 pairs of tumor and corresponding normal adjacent tissue [Mean Ct values (mean β-actin Ct value)].

<p>BLQ: Below limit of quantification (Ct≤38); High mRNA levels (Ct ≤35) are in bold; *Mean ± standard deviation of samples with Ct ≤38 of each CYP gene; n = number of samples with Ct value ≤38. Experiments performed in triplicate.</p

Associations of the clinicopathological factors with CYP2E1 and CYP2W1 mRNA expression.

§<p>Mann-Whitney rank test.</p>£<p>Spearman rank correlation test.</p><p>*Statistically significant p<0.05.</p

Demographic and clinical features of patients involved in the study.

<p>*Primary sites: EX = Extremities; GU = Genitourinary; H&N = Head and Neck.</p

Levels of normalized mRNA Expression of (a) CYP1B1, (b) CYP2E1, (c) CYP2W1, (d) CYP3A4 and (e) CYP3A5 in 13 pairs of tumor and corresponding normal adjacent tissue from patients with RMS.

<p>Transcript levels of each CYP gene were normalized to β-actin and expressed per μg of total RNA. Values represent means and average of standard deviations of expression levels determined in triplicate. *p<0.05.</p

Summary of RT qPCR and Western data in four different patients.

<p>N, normal adjacent tissue; T, tumor tissue. For RT qPCR (PCR) data: −, undetectable amounts of mRNA; +, detectable mRNA expression; +^#, high amounts of mRNA. For Western (W) analysis: −, not detected; +, positive detection; (+), weak detection.</p

Western blots analysis of CYP proteins.

<p>(A) Representative immunoblots of CYP1B1, CYP2E1, CYP2W1, CYP3A4, and CYP3A5 proteins from non-tumor tissues (N) and tumor tissues (T) of RMS patients: 2, 5, 6, and 12. (B) The levels of β-actin were analyzed to ensure samples’ loading amount.</p